Osteoarthritis Structure Claim May Be Separable From Symptom Change - FDA
This article was originally published in The Gray Sheet
Executive Summary
An osteoarthritis (OA) labeling claim for slowing of structural deterioration may be separable from claims for improvement in patient symptoms, FDA says in a revised July 15 draft guidance.